Worldwide Clinical Trials

DECEMBER 12, 2022

Genetic testing provides patients with a diagnosis for their illness, helps patients and family members to understand risks of developing new diseases, and can be used to support clinical trial advancement. Can prior genetic testing results be utilized in a trial, or should a new genetic sample be taken before participating?

Clinical Trials 130

Clinical Trials Clinical Trials Genetics Trials 130

Worldwide Clinical Trials

AUGUST 14, 2024

The analysis of circulating tumor DNA (ctDNA) in a liquid biopsy can also permit genotyping and help monitor the effectiveness of chemotherapy. The post The Role of Oncology Biomarkers in Personalizing Hematology Treatment Plans appeared first on Worldwide Clinical Trials.

Genetics 195

Genetics Protein Gene Genotype 195

pharmaphorum

JANUARY 18, 2023

The DNA of these so-called ‘genetic superheroes’ may contain clues about how to treat severe disease. In our experience of running 20+ precision medicine studies, there are a few design principles that every research programme – from biobanks to clinical trials – should consider. Giving participants something in return.

Genetic Disease 97

Genetic Disease Genetics Research Genome 97

XTalks

SEPTEMBER 28, 2020

Related: Liquid Biopsies Help Match Cancer Patients to Phase I Trials. The test is based on the detection of actionable genes – genes with known driver mutations that can be targeted by an approved therapy (or investigational therapies in clinical trials). In the US, Medicare covers the test.

Gene 105

Gene DNA Life Science Genotype 105

Bioengineer

JANUARY 16, 2024

Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms.

Genome 119

Genome Genomics Protein In-Vitro 119

XTalks

JANUARY 21, 2025

In a clinical trial, participants demonstrated a 98% success rate after six months post implantation, with arteries widened successfully and no stent fractures observed. The Shield test provides a non-invasive approach to colorectal cancer screening by analyzing blood for key DNA changes linked to cancer. Photo courtesy of BD.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

XTalks

FEBRUARY 4, 2021

Through these collaborations, cohort research dataset sharing programs allow for whole-genome sequence and genotype data to be made available for independent research. The project began in 2004, in the early days of biobanking for DNA, says Dr. Bernard, and has grown tremendously since.

Research 98

Research Biobanking Drugs Genomics 98